Methods of using OX40 ligand encoding polynucleotides
AssigneeModernaTX, Inc.
InventorsJoshua P. Frederick, Ailin Bai
Life of this patent
Estimating the term…
Abstract
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
Claims20
A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject a lipid nanoparticle (LNP) encapsulated messenger RNA (mRNA) encoding a human OX40L polypeptide, thereby activating T cells in vivo, to treat cancer in the subject.
A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject a lipid nanoparticle (LNP) encapsulated messenger RNA (mRNA) encoding a human OX40L polypeptide, wherein the mRNA comprises an open reading frame comprising a nucleotide sequence at least 90% identical to SEQ ID NO:
- 4, thereby activating T cells in vivo, to treat cancer in the subject.
A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject a lipid nanoparticle (LNP) encapsulated messenger RNA (mRNA) encoding a human OX40L polypeptide, wherein the mRNA comprises a nucleotide sequence at least 90% identical to SEQ ID NO:
- 65, thereby activating T cells in vivo, to treat cancer in the subject.
Dependencies are inferred from the claim text.